Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Consun Pharmaceutical Group Limited (1681.HK)
Guangzhou, CN
Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.36% | -1.32% | -12.58% | -21.22% | -4.38% | -9.34% | +33.52% | +196.65% | +146.61% | +255.39% | +189.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+15.2% ★ Q4'25: +25.7% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+15.6% Q4'25: +25.9% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+33.1% Q4'25: +40.1% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+33.7% ★ Q4'25: +34.5% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+94.9% ★ Q4'25: +204.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.8% Q4'25: +6.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.18× ★ Q4'25: 0.08× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
571.77M
est: 629.29M (-9.1%)
|
730.68M
est: 791.14M (-7.6%)
|
831.11M
est: 1.01B (-17.4%)
|
1.22B
est: 1.09B (+12.5%)
|
1.66B
est: 1.97B (-15.7%)
|
1.84B
est: 2.24B (-17.5%)
|
1.73B
est: 2.22B (-22.2%)
|
1.75B
est: 2.04B (-14.2%)
|
2.04B
est: 2.47B (-17.4%)
|
2.34B
est: 2.57B (-8.9%)
|
2.59B
est: 2.55B (+1.7%)
|
2.97B
est: 2.95B (+0.4%)
|
3.42B
est: 3.48B (-1.7%)
|
4.02B
4.00B – 4.05B
+15.8% YoY
|
4.48B
4.45B – 4.53B
+11.3% YoY
|
4.95B
4.92B – 4.99B
+10.5% YoY
|
| EBITDA |
218.15M
est: 222.75M (-2.1%)
|
250.69M
est: 280.86M (-10.7%)
|
312.52M
est: 301.78M (+3.6%)
|
437.52M
est: 389.55M (+12.3%)
|
597.46M
est: 718.98M (-16.9%)
|
723.71M
est: 665.50M (+8.7%)
|
569.49M
est: 666.47M (-14.6%)
|
618.79M
est: 165.76M (+273.3%)
|
728.71M
est: 190.53M (+282.5%)
|
785.89M
est: 199.45M (+294.0%)
|
963.06M
est: 902.03M (+6.8%)
|
1.05B
est: 1.04B (+0.2%)
|
1.21B
est: 1.23B (-1.8%)
|
1.42B
1.42B – 1.43B
+15.8% YoY
|
1.59B
1.57B – 1.60B
+11.3% YoY
|
1.75B
1.74B – 1.77B
+10.5% YoY
|
| EBIT |
205.83M
est: 202.98M (+1.4%)
|
235.46M
est: 264.64M (-11.0%)
|
293.93M
est: 284.69M (+3.2%)
|
398.45M
est: 378.93M (+5.2%)
|
533.43M
est: 664.27M (-19.7%)
|
655.33M
est: 651.47M (+0.6%)
|
496.38M
est: 682.97M (-27.3%)
|
550.13M
est: 138.71M (+296.6%)
|
660.18M
est: 159.44M (+314.1%)
|
715.41M
est: 166.90M (+328.6%)
|
884.97M
est: 833.66M (+6.2%)
|
974.99M
est: 965.08M (+1.0%)
|
1.15B
est: 1.14B (+1.3%)
|
1.32B
1.31B – 1.32B
+15.8% YoY
|
1.47B
1.46B – 1.48B
+11.3% YoY
|
1.62B
1.61B – 1.63B
+10.5% YoY
|
| Net Income |
152.88M
est: 101.45M (+50.7%)
|
211.20M
est: 192.22M (+9.9%)
|
249.69M
est: 227.61M (+9.7%)
|
307.53M
est: 280.08M (+9.8%)
|
396.24M
est: 509.31M (-22.2%)
|
465.35M
est: 461.18M (+0.9%)
|
79.82M
est: 493.38M (-83.8%)
|
498.79M
est: 68.05M (+633.0%)
|
590.17M
est: 78.22M (+654.5%)
|
682.91M
est: 734.07M (-7.0%)
|
784.53M
est: 836.12M (-6.2%)
|
910.46M
est: 951.24M (-4.3%)
|
1.08B
est: 1.05B (+2.3%)
|
1.27B
1.27B – 1.28B
+20.9% YoY
|
1.39B
1.37B – 1.42B
+9.4% YoY
|
1.53B
1.49B – 1.58B
+10.0% YoY
|
| SGA |
255.62M
est: 279.45M (-8.5%)
|
345.10M
est: 321.34M (+7.4%)
|
381.99M
est: 371.92M (+2.7%)
|
516.03M
est: 480.28M (+7.4%)
|
703.76M
est: 854.62M (-17.7%)
|
738.06M
est: 819.10M (-9.9%)
|
700.69M
est: 782.52M (-10.5%)
|
746.00M
est: 657.34M (+13.5%)
|
900.00M
est: 755.56M (+19.1%)
|
1.09B
est: 790.92M (+38.4%)
|
1.17B
est: 1.14B (+2.4%)
|
1.29B
est: 1.32B (-2.1%)
|
1.52B
est: 1.56B (-2.5%)
|
1.80B
1.79B – 1.81B
+15.8% YoY
|
2.01B
1.99B – 2.03B
+11.3% YoY
|
2.22B
2.20B – 2.24B
+10.5% YoY
|
| EPS |
0.20
est: 0.12 (+64.0%)
|
0.21
est: 0.18 (+19.2%)
|
0.25
est: 0.30 (-16.7%)
|
0.32
est: 0.34 (-5.6%)
|
0.46
est: 0.55 (-16.2%)
|
0.54
est: 0.59 (-8.9%)
|
0.09
est: 0.69 (-86.4%)
|
0.61
est: 0.68 (-9.7%)
|
0.74
est: 0.82 (-10.0%)
|
0.86
est: 0.89 (-3.8%)
|
0.98
est: 0.98 (+0.4%)
|
1.11
est: 1.11 (0.0%)
|
1.27
est: 1.23 (+3.0%)
|
1.49
1.49 – 1.49
+20.9% YoY
|
1.63
1.60 – 1.66
+9.4% YoY
|
1.79
1.74 – 1.85
+9.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-27 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Cambria Emerging Shareholder Yield ETF EYLD | 0.98% | 8.28M | 0.65% |
| 2 | Sophus Capital Emerging Market Small Cap ETF EMSC | 0.50% | 222.3K | 0.85% |
| 3 | iShares MSCI China Small-Cap ETF ECNS | 0.49% | 317.7K | 0.59% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.09% | 109.3K | 0.42% |
| 5 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.08% | 281.7K | 0.58% |
| 6 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.07% | 50.1K | 0.74% |
| 7 | State Street SPDR S&P China ETF GXC | 0.06% | 265.8K | 0.59% |
| 8 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 380.8K | 0.65% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.05% | 283.5K | 0.55% |
| 10 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 174.4K | 0.72% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Meng An | Chief Executive Officer & Executive Chairman | 27M | male |
| Yuk Chuen Young | Executive Director | 1M | male |
| Quan Zhu | Chief Scientist & Non-Executive Director | 857.5K | — |
| Yujun Chen | Chief Financial Officer | 38.1K | female |
| Lei Zhou | Assistant President | — | — |
| Lianhui Chen | Chairman & GM of Consun Pharmaceutical (Horgos) Co., LTD. | — | female |
| Haien Gao | Company Secretary | — | male |
| Guorong Guo | Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1681.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
